S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead

Chemed (CHE) Competitors

$588.41
+2.37 (+0.40%)
(As of 02/21/2024 ET)

CHE vs. AMED, OPCH, SWAV, ROIV, IMGN, THC, ASND, NTRA, BIO, and BIO.B

Should you be buying Chemed stock or one of its competitors? The main competitors of Chemed include Amedisys (AMED), Option Care Health (OPCH), Shockwave Medical (SWAV), Roivant Sciences (ROIV), ImmunoGen (IMGN), Tenet Healthcare (THC), Ascendis Pharma A/S (ASND), Natera (NTRA), Bio-Rad Laboratories (BIO), and Bio-Rad Laboratories (BIO.B). These companies are all part of the "medical" sector.

Chemed vs.

Amedisys (NASDAQ:AMED) and Chemed (NYSE:CHE) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, community ranking, media sentiment and institutional ownership.

Amedisys has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Chemed has lower revenue, but higher earnings than Amedisys. Chemed is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$2.23B1.37$118.61M$0.071,337.29
Chemed$2.13B4.15$249.62M$16.1536.43

95.7% of Amedisys shares are owned by institutional investors. Comparatively, 94.3% of Chemed shares are owned by institutional investors. 1.8% of Amedisys shares are owned by insiders. Comparatively, 3.8% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Amedisys had 10 more articles in the media than Chemed. MarketBeat recorded 19 mentions for Amedisys and 9 mentions for Chemed. Chemed's average media sentiment score of 0.70 beat Amedisys' score of 0.52 indicating that Amedisys is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amedisys
6 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Chemed
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Chemed has a net margin of 10.99% compared to Chemed's net margin of 0.12%. Amedisys' return on equity of 32.87% beat Chemed's return on equity.

Company Net Margins Return on Equity Return on Assets
Amedisys0.12% 13.45% 7.45%
Chemed 10.99%32.87%20.20%

Amedisys received 161 more outperform votes than Chemed when rated by MarketBeat users. However, 63.30% of users gave Chemed an outperform vote while only 58.75% of users gave Amedisys an outperform vote.

CompanyUnderperformOutperform
AmedisysOutperform Votes
487
58.75%
Underperform Votes
342
41.25%
ChemedOutperform Votes
326
63.30%
Underperform Votes
189
36.70%

Amedisys presently has a consensus price target of $102.25, suggesting a potential upside of 9.23%. Chemed has a consensus price target of $614.50, suggesting a potential upside of 4.43%. Given Chemed's higher probable upside, research analysts plainly believe Amedisys is more favorable than Chemed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amedisys
0 Sell rating(s)
8 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Chemed
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Chemed beats Amedisys on 10 of the 18 factors compared between the two stocks.


Get Chemed News Delivered to You Automatically

Sign up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHE vs. The Competition

MetricChemedHome health care services IndustryMedical SectorNYSE Exchange
Market Cap$8.86B$2.86B$4.97B$17.22B
Dividend Yield0.27%0.27%2.92%3.55%
P/E Ratio36.43284.61119.7324.83
Price / Sales4.151.372,966.636.95
Price / Cash24.2513.2990.8117.87
Price / Book10.963.574.306.18
Net Income$249.62M-$9.76M$112.59M$868.85M
7 Day Performance1.58%-1.60%1.63%0.39%
1 Month Performance-1.01%-1.04%7.20%2.62%
1 Year Performance14.96%-0.56%7.09%69.21%

Chemed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMED
Amedisys
2.0339 of 5 stars
$93.61
-0.4%
$103.22
+10.3%
+0.4%$3.05B$2.22B1,337.4820,000Analyst Report
OPCH
Option Care Health
4.1221 of 5 stars
$32.25
-2.6%
$37.17
+15.2%
+16.5%$5.71B$3.94B22.878,058Positive News
SWAV
Shockwave Medical
4.1071 of 5 stars
$231.81
-1.6%
$263.00
+13.5%
+37.7%$8.55B$489.73M36.111,001Earnings Report
Insider Selling
ROIV
Roivant Sciences
4.1163 of 5 stars
$10.80
-0.6%
$16.56
+53.3%
+34.7%$8.68B$61.28M-8.18904Analyst Revision
IMGN
ImmunoGen
4.0466 of 5 stars
$31.23
flat
$25.77
-17.5%
+692.6%$8.32B$108.78M-100.74277Analyst Report
THC
Tenet Healthcare
4.6285 of 5 stars
$88.07
-2.7%
$92.47
+5.0%
+53.2%$8.94B$20.55B15.42102,400Positive News
ASND
Ascendis Pharma A/S
1.681 of 5 stars
$143.35
-0.9%
$154.75
+8.0%
+39.9%$8.27B$288.08M-15.50879Gap Down
NTRA
Natera
0.967 of 5 stars
$68.40
-3.6%
$71.54
+4.6%
+47.3%$8.22B$820.22M-15.133,018Upcoming Earnings
Analyst Upgrade
BIO
Bio-Rad Laboratories
4.7852 of 5 stars
$316.10
-3.1%
$498.50
+57.7%
-27.7%$9.21B$2.80B-54.038,200Earnings Report
Analyst Upgrade
BIO.B
Bio-Rad Laboratories
0 of 5 stars
$321.02
flat
N/A-12.8%$9.36B$2.80B-54.887,900

Related Companies and Tools

This page (NYSE:CHE) was last updated on 2/22/2024 by MarketBeat.com Staff